Tranzbyte Corporation (OTCMKTS:ERBB) announced that it will change its corporate name to AMERICAN GREEN.The name change should be effective sometime within the next several weeks and is subject to review by FINRA and The State of Nevada.Shareholders needn’t do anything regarding the shares they own since the company’s stock symbol, ERBB, will remain the same and there will be no restructuring of the company’s share or management structure.The name, American Green, and the internet domain, americangreen.com, are registered and owned by the Company. Tranzbyte Corp (OTCMKTS:ERBB) on last trading day company shares ended up $0.0294 .
VIVUS Inc (NASDAQ:VVUS) announced that a poster describing results of an analysis of the association between weight loss with Qsymia® (phentermine and topiramate extended-release) capsules CIV and annual concomitant medication costs will be presented at the AACE 23rd Annual Scientific & Clinical Congress at the Paris Las Vegas Hotel, Las Vegas, NV. VIVUS, Inc. (NASDAQ:VVUS) shares moved down -3.64% in last trading session and was closed at $5.03, while trading in range of $5.03 – $5.22. VIVUS, Inc. (NASDAQ:VVUS) year to date (YTD) performance is -44.60%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that clinical data on Iclusig(R) (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.65. Company weekly volatility is calculated as 4.53% and price to cash ratio as 5.24. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -1.48%.
TherapeuticsMD Inc (NASDAQ:TXMD) Director Robert Lapenta, Jr. acquired 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, May 9th. The shares were purchased at an average cost of $3.66 per share, for a total transaction of $18,300.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $36,600.TherapeuticsMD Inc (NYSEMKT:TXMD) weekly performance is 8.19%. On last trading day company shares ended up $3.83. Analysts mean target price for the company is $9.75. TherapeuticsMD Inc (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is -31.45%.